In recent years, traditional cancer therapies such as chemotherapy and radiotherapy have reached a plateau in terms of effectiveness, underscoring the need for innovative and targeted therapeutic approaches. Immunotherapy, specifically therapeutic cancer vaccines, have emerged as promising alternatives, boosting the immune system to combat cancer more safely, effectively, and specifically. In the present study, we addressed one of the main challenges associated with using mRNA as a therapeutic agent: its instability and susceptibility to degradation. The mRNA used encodes Ovalbumin, a specific antigen presented to monocytes differentiated into antigen-presenting cells (APCs), triggering a targeted and enhanced immune response against cancer cells.